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Background: Left ventricular hypertrophy (LVH) is a valid predictor for cardiovascular mortality and morbidity
regardless of age, gender, and race. The HyperGEN study conducted a genome-wide association study and identified
twelve single nucleotide polymorphisms (SNPs) associated with LVH. The aim of this study was to validate these
candidate SNPs in the Korean population.
Methods: Among 1637 individuals from the Korean Multi-Rural Communities Cohort Study (MRCohort) of the Korean
Genome Epidemiology Study (KoGES), we carried out a linear regression analysis with left ventricular mass index (LVMI)
and a logistic regression analysis for LVH status.
Results: The rs4129218 on chromosome 12 tended to be associated with LVM/body surface area (adjusted β = −0.023;
p = 0.036) and LVM/height2.7 (adjusted β = −0.027; p = 0.016), and was marginally protective against LVH after
adjustment for age, sex, body mass index, serum creatinine, systolic blood pressure, heart rate and antihypertensive
medication (adjusted odds ratio = 0.766 and 0.731; p = 0.027 and 0.007 according to indexation by BSA and height2.7,
respectively).
Conclusions: In the Korean population, the minor allele of rs4129218 had borderline association with lower LVM. This
study suggests that rs4129218 on chromosome 12 showed consistent tendency of possibly related loci for LVH
independent of ethnic background.
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Left ventricular hypertrophy (LVH) is a well-known risk
factor for cardiovascular morbidity and mortality. In-
creased LV wall thickness predicts cardiovascular disease
events [1], and dilatation of LV predicts congestive heart
failure [2]. LVH and increased LV mass (LVM) are risk
factors of coronary artery disease, congestive heart
disease and stroke [3-7].
LVM is influenced by multifactorial traits, such as
blood pressure (BP), obesity, body size, and gender
[8-12], which can explain only one-half to two-thirds of
the inter-individual variability of LVM. Additionally,
genetic susceptibility is expected to be associated with* Correspondence: jhs2003@hanyang.ac.kr
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unless otherwise stated.degree of hypertrophy regardless of race [13-17]. Several
lines of evidence have indicated that echocardiographic
LV geometry and LVH show heritability [13,14,18-20].
Recently, genome-wide association studies (GWAS),
such as the HyperGEN study have identified several
SNPs associated with echocardiography LVH in Western
populations [21].
However, the single nucleotide polymorphisms (SNPs)
suggested in the HyperGEN study have not been vali-
dated for Asian populations with different lifestyles, en-
vironmental backgrounds and genetic differences [16].
Although a previous study performed a GWAS for elec-
trocardiographic LVH in Asian populations [22], no report
concerning the genetic association of echocardiographic
LVH has been published. Therefore, we conducted a valid-
ation study of candidate SNPs reported in the HyperGEN
study in relation to LVH in the Korean population.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Study subjects
The Yang-pyeong cohort is part of the Korean Multi-Rural
Communities Cohort Study (MRCohort) of the Korean
Genome Epidemiology Study (KoGES), which began in
2005. A total of 1841 men and women aged ≥44 years
living in Yang-pyeong County in Korea were voluntarily
recruited. Among them, we included 1745 subjects
whose echocardiographic data were available in the
analysis and excluded 108 subjects who had poor
acoustic image quality, an interrogation angle >10°, any
regional wall motion abnormalities, grade II or greater
valvular regurgitation, any valvular stenosis, pericardial
disease, cardiomyopathy on echocardiography, and
atrial fibrillation. Finally, 1637 subjects (men 671 and
women 966) were included in the study. The study was
conducted according to the guidelines of the Declar-
ation of Helsinki, and all procedures involving human
subjects were approved by the institutional review
board of Hanyang University. Written informed con-
sent was obtained from all subjects.Echocardiographic measurement
All tests were performed by a single sonographer using a
commercially available machine, (HP SONOS 2500;
Hewlett-Packard, Inc., Andover, MA, USA) using a 2.5/
2.0-MHz transducer. The sonographer was blinded to
the patient’s clinical data. Images were obtained in the
supine and left lateral positions, in the parasternal long-
axis and short-axis views, and in the apical four- and
two-chamber views. Left ventricular measurements were
performed at or just below the mitral valve tips, by the
leading edge-to-leading edge method, according to the
recommendations of the American Society of Echocardi-
ography (ASE) [23], with the M-mode guided by the
two-dimensional examination. LV systolic and diastolic
diameters, as well as interventricular septal and posterior
wall thickness were measured at end-diastole, which was
defined by the beginning of the QRS complex. LVM was
calculated using the corrected ASE formula proposed by
Devereux et al.
LVM = 1.04 × [(LVID + PWT+ IVST)3 ‐ LVID3] × 0.8 +
0.6 [24].
Where, LVID, PWT, and IVST represent the LV in-
ternal dimension (cm), LV posterior wall thickness
(cm) and interventricular septal thickness (cm), re-
spectively. LVM was indexed for body surface area
(LVM/BSA, g/m2), which was calculated by the Dubois
formula, and for height2.7 (LVM/height2.7, g/m2.7), as
recommended by De Simone et al. We set cut-off
values for LVH as LVM/BSA ≥ 116 g/m2 in males and ≥
96 in females and LVM/height2.7 ≥ 49 g/m2.7 in males
and ≥ 45 g/m2.7 in females [25].General characteristics, anthropometrics, and biochemical
variables
Subjects were interviewed by trained interviewers using
a structured questionnaire to determine general charac-
teristics, including age and antihypertensive medication.
Height was measured using a standard height scale to
the nearest 0.1 cm, and weight was measured with a
metric weight scale to the nearest 0.01 kg in light cloth-
ing without shoes. Body mass index (BMI) was calcu-
lated by dividing the weight (kg) by height (m2). Waist
circumference (WC) was measured halfway between the
lowest rib margin and the iliac crest. We measured
seated BP from the right arm by auscultation using a
standard sphygmomanometer and a standard cuff. Two
consecutive measurements of BP were taken after each
subject had been sitting for at least 5 min. Systolic and
diastolic BP were recorded to the nearest 2 mmHg. If
the two systolic or diastolic BP readings were more than
5 mmHg apart, an additional measurement was per-
formed, and the mean value of the closest two measure-
ments was used for the subsequent analyses. Blood
samples were collected in the morning after at least 8 h
of fasting. Plasma total cholesterol, triglyceride, glucose
and high-density lipoprotein cholesterol levels were
measured with an ADVIA1650 Automatic Chemistry
Analyzer (Siemens, New York, NY, USA).
SNP selection and genotyping
Twelve SNPs from the HyperGEN study were included.
Before genotyping candidate SNPs, three SNPs from the
HyperGEN study (rs1833534, rs4129000 and rs238688)
were filtered out because they had a minor allele frequency
(MAF) lower than 0.05 in the Chinese and Japanese Hap-
Map database [26]. Finally, nine SNPs were included for
genotyping in the present study. Genotyping was per-
formed with the use of Sequenom iPLEX (San Diego,
USA) at the Analytical Genetics Technology Centre,
Princess Margaret Hospital/University Health Network
in Toronto, Canada. Polymerase chain reaction (PCR)
primers were designed in a region of approximately 100
base pairs around the SNP of interest and an extension
primer was designed immediately adjacent to the SNP.
After PCR amplification, Shrimp Alkaline Phosphatase
(SAP) was added, along with the primer extension mix-
ture after a brief incubation. After a standardized PCR
program, SpectroCLEAN resin was added to the mix-
ture to prepare it for spotting and detection of the PCR
products using a 384-well SpectroChip® and a Compact
TM MALDI-TOF mass-spectrometer automatically.
Statistical analysis
The descriptive analysis was performed using SPSS
(Statistical Package for the Social Sciences) software
(version 19.0; SPSS Inc., Chicago, Illinois, USA). The
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of LVM/BSA and LVM/height2.7, and the categorical
phenotype of LVH, which was defined as aforementioned
cut-off value [25]. LVMI was transformed into a natural
log value to normalize the trait distribution. Multiple lin-
ear and logistic regressions with a dominant model were
performed using PLINK 1.07 software (http://pngu.mgh.
harvard.edu/~purcell/plink) [27], adjusting for age, gender,
BMI, serum creatinine, systolic BP, heart rate, and anti-
hypertensive medication. The HWE tests were con-
ducted using PLINK. A P value <0.0056 (0.05 with 9
SNPs) was deem statistically significant to account for
multiple testing.Results
The general characteristics of study subjects are shown
in Table 1. The mean age was 61.2 ± 10.4 years, and the
proportion of men was 41.0%. The study subjects had a
somewhat high BMI and WC (mean BMI, 24.7 ± 3.3 kg/
m2; mean WC, 87.8 ± 8.3 cm). Systolic and diastolic BP
were 124.3 ± 17.7 mmHg and 79.9 ± 10.6 mmHg, respect-
ively. The prevalence of hypertension was 44.3% and 483
(29.5%) subjects had taken antihypertensive medication.
Echocardiographic data are presented in Table 2. The
mean LVM/BSA and LVM/height2.7 were 95.6 ± 22.5 g/
m2 and 45.4 ± 11.9 g/m2.7, respectively. Four hundred
ninety one (30.0%) and 644 (39.3%) subjects were diag-
nosed with LVH according to indexation by BSA and
height2.7, respectively.Table 1 Demographic and clinical characteristics of the study
Characteristics Total
(n = 1637)
Age, years 61.2 ± 10.4
Body mass index, kg/m2 24.7 ± 3.3
Waist circumference, cm 87.8 ± 8.3
Systolic blood pressure, mmHg 124.3 ± 17.7
Diastolic blood pressure, mmHg 79.9 ± 10.6
Pulse pressure, mmHg 44.4 ± 13.1
Heart rate, bpm 69.7 ± 10.1
Fasting glucose, mmol/l 5.7 ± 1.4
Total cholesterol, mmol/l 5.14 ± 0.96
Triglyceride, mmol/l 1.76 ± 1.10
High-density lipoprotein cholesterol, mmol/l 1.19 ± 0.28
Serum creatinine, μmol/l 85.7 ± 15.91
Hypertension, n (%) 726 (44.3%)
Antihypertensive medication, n (%) 483 (29.5%)
Data are presented as mean ± SD unless otherwise indicated.Table 3 lists the nine candidate SNPs associated with
echocardiographic LVH from the HyperGEN study. The
SNPs examined did not significantly deviate from Hardy-
Weinberg equilibrium. In Tables 4 and 5, one SNP
(rs4129218 on chromosome 12) among the nine candidate
SNPs from the HyperGEN study had a marginally negative
linear correlation with LVM/BSA (adjusted beta = −0.023;
95% CI, −0.044–−0.001; P = 0.036) and LVM/height2.7 (ad-
justed beta = −0.027; 95% CI, −0.048–−0.005; P = 0.016)
and its effect sizes are shown in Figure 1. This SNP, lo-
cated in the LOC100507065 gene (Table 3), tended to
show a protective effect on LVH defined as LVM/BSA (ad-
justed OR = 0.766; 95% CI, 0.605–0.970; P = 0.027) and
LVM/height2.7 (adjusted OR = 0.731; 95% CI, 0.582–0.919;
P = 0.007). However, the P values did not meet statistical
threshold (P <0.0056). In subgroup analysis, these find-
ings were consistently observed in hypertensive sub-
jects (Additional file 1: Table S1B and S2B, P = 0.035
and 0.021, respectively). Another SNP, rs6450415 on
chromosome 5 also revealed an association with LVH de-
fined as LVM/BSA (adjusted OR = 1.463; 95% CI, 1.148–
1.865; P = 0.002) and LVM/height2.7 (adjusted OR = 1.320;
95% CI, 1.041–1.673; P = 0.022). However, no significant
associations were noted in quantitative analysis (p = 0.107
and 0.178, respectively). In subgroup analysis, an associ-
ation between rs6450415 and LVH was remained in only
non-hypertensive subjects (Additional file 1: Table S1A
and S2A, P = 0.002 and 0.013, respectively) but, not in
hypertensive subjects (Additional file 1: Table S1B and
S2B, P = 0.174 and 0.567, respectively).population
Men Women P
value(n = 671) (n = 966)
61.8 ± 10.2 60.7 ± 10.5 0.040
24.2 ± 3.1 25.0 ± 3.4 <0.001
88.3 ± 7.9 87.5 ± 8.5 0.078
125.8 ± 17.2 123.2 ± 18.0 0.004
81.5 ± 11.0 78.8 ± 10.1 <0.001
44.4 ± 12.5 44.5 ± 13.4 0.855
69.2 ± 10.3 70.0 ± 10.0 0.135
5.8 ± 1.4 5.7 ± 1.4 0.050
4.92 ± 0.91 5.29 ± 0.98 <0.001
1.89 ± 1.23 1.68 ± 0.98 <0.001
1.16 ± 0.30 1.21 ± 0.27 <0.001
95.5 ± 13.3 78.7 ± 14.1 <0.001
286 (42.6%) 440 (45.5%) 0.245
157 (23.4%) 326 (33.7%) <0.001
Table 2 Echocardiographic data
Total Men Women P
value(n = 1637) (n = 671) (n = 966)
LVID, cm 4.89 ± 0.46 5.02 ± 0.44 4.79 ± 0.45 <0.001
LVWT, cm 1.80 ± 0.24 1.87 ± 0.22 1.75 ± 0.24 <0.001
LVM, g 155.1 ± 40.0 167.0 ± 38.6 144.7 ± 37.6 <0.001
LVM/BSA, g/m2 95.6 ± 22.5 98.3 ± 20.8 93.7 ± 23.4 <0.001
LVM/height2.7, g/m2.7 45.4 ± 11.9 43.9 ± 10.2 46.5 ± 12.9 <0.001
Prevalence of LVH, n (%)
Indexation by BSA 491 (30.0%) 116 (17.3%) 375 (38.8%) <0.001
Indexation by height2.7 644 (39.3%) 179 (26.7%) 465 (48.1%) <0.001
Data are presented as mean ± SD unless otherwise indicated.
Abbreviations: LVID, left ventricular internal dimension; LVM, left ventricular mass; LVM/BSA, left ventricular mass indexed by body surface area; LVM/height2.7, left
ventricular mass indexed by height2; LVH, left ventricular hypertrophy; LVWT, left ventricular wall thickness.
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In this study, we successfully analyzed nine of the 12 can-
didate SNPs from the HyperGEN study in the Korean
population. Among the nine candidate SNPs, two SNPs
(rs6450415 on chromosome 5 and rs4129218 on chromo-
some 12) showed borderline association with LVH.
Among them, only rs4129218 had marginal association
with two types of LVMI in a quantitative trait study.
To our knowledge, the present study is the first replica-
tion study concerning SNPs for echocardiographic LVH in
an Asian population. A previous study identified several
candidate SNPs via GWAS for LVH in the Korean popula-
tion [22], which was a study on electrocardiographic LVH.
Although LVH using electrocardiography showed a stron-
ger correlation with the genetic signal than LVH using
echocardiography (39–41% versus 21–29%) [28], the
electrocardiographic LVH and echocardiographic LVH
predicted mortality independently and carried different
prognostic information [29]. Therefore, SNPs associatedTable 3 Genotyping of nine SNPs from the HyperGEN study i
SNP Chromosome Position* Near Gene
rs409045 5 34,628,522 RAI14
rs6450415 5 57,053,058 MIER3
rs6961069 7 80,589,645 CD36
rs10499859 7 80,629,494 CD36
rs4129218 12 65,564,881 LOC1005070
rs1155635 13 70,373,320
rs2415872 14 44,638,258 LOC1019273
rs756529 20 49,394,471 KCNB1
rs10483186 22 34,943,863 RP1-272 J12
*dbSNP positions are given according to National Center for Biotechnology Informa
Map Viewer Build 37.
Abbreviations: HWE, Hardy-Weinberg equilibrium; LVMI, left ventricular mass index;with echocardiographic LVH may be different from SNPs
associated with electrocardiographic LVH.
Arnett DK et al. demonstrated that three SNPs includ-
ing rs409045 on chromosome 5, rs4129000 and rs4129218
on chromosome 12 showed a significant association with
log-transformed LVMI in Caucasian subjects (P = 0.010,
0.035, and 0.007, respectively), and only rs4129218 tended
to be significant for LVH (P = 0.038). In the present study,
rs4129218 showed a marginal association with LVH, con-
sistent with that in Caucasians. In the validation study for
African American subjects, they reported associations of
another two SNPs (rs238688 and rs756529 on chromo-
some 20) with log-transformed LVMI or LVH. In the
present study, the association of rs756529 was not signifi-
cant and rs238688 was monomorphic. There was no com-
mon finding between Caucasian and African American
subjects in the HyperGEN study. GWAS was performed
only in Caucasians, which likely led to different results
in Caucasians and African Americans. Furthermore,n the Korean population




Intron G 0.296 0.288
65 G 0.227 0.353
G 0.423 0.958
51 Intron C 0.328 0.541
Intron G 0.391 0.56
.1 Intron T 0.384 0.736
tion.
MAF, minor allele frequency; SNP, single nucleotide polymorphism.
Table 4 Association analyses between left ventricular mass indexed by BSA and nine candidate SNPs from the
HyperGEN study in the Korean population
Log (LVM/BSA) LVH
SNP LVM/BSA, g/m2 Beta§ L95 U95 P value OR§ L95 U95 P value
rs409045 −0.023 0.048 0.001 0.060 0.787 0.601 1.031 0.083
TT (n = 1239) 95.9 ± 22.5
CT + CC (n = 398) 94.3. ± 22.3
rs6450415 0.018 −0.004 0.041 0.107 1.463 1.148 1.865 0.002
TT (n = 1118) 95.2 ± 22.5
CT + CC (n = 519) 96.4 ± 22.3
rs6961069 0.001 −0.020 0.022 0.932 1.190 0.946 1.496 0.137
TT (n = 808) 95.5 ± 21.8
CT + CC (n = 829) 95.6 ± 23.1
rs10499859 0.001 −0.020 0.022 0.945 1.180 0.938 1.484 0.156
AA (n = 799) 95.6 ± 21.8
AG + GG (n = 838) 95.4 ± 23.1
rs4129218 −0.023 −0.044 −0.001 0.036 0.766 0.605 0.970 0.027
AA (n = 975) 96.6 ± 23.0
AG + GG (n = 662) 94.0 ± 21.5
rs1155635 −0.002 −0.025 0.020 0.831 0.905 0.710 1.153 0.420
AA (n = 543) 95.8 ± 22.5
GA + GG (n = 1081) 95.5 ± 22.5
rs2415872 −0.013 −0.034 0.008 0.236 0.855 0.680 1.075 0.181
GG (n = 735) 96.2 ± 22.4
GC + CC (n = 902) 95.0 ± 22.5
rs756529 0.015 −0.007 0.037 0.173 1.234 0.972 1.568 0.085
AA (n = 609) 94.4 ± 21.7
GA + GG (n = 1028) 96.3 ± 22.9
rs10483186 −0.006 −0.027 0.016 0.586 0.999 0.790 1.264 0.996
GG (n = 622) 96.2 ± 23.0
GT + TT (n = 1015) 95.2 ± 22.1
§Analysis adjusted for age, gender, body mass index, serum creatinine, systolic blood pressure, heart rate and antihypertensive medication.
Abbreviations: L95 and U95, confidence interval lower and upper 95%; LVH, left ventricular hypertrophy defined as LVM/BSA ≥ 116 g/m2 in males and ≥ 96 g/m2 in
females; LVM/BSA, left ventricular mass indexed by body surface area; SNP, single nucleotide polymorphism.
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ent allele frequencies between the two ethnic subjects,
and other risk factors for LVH may also have differed
between subjects.
Rs4129218 is located on LOC100507065, uncharacter-
ized lincRNA (large intergenic non-coding RNA), between
MSRB3 (methionine sulfoxide reductase B3) at ~98 kb
and RPSAP52 (ribosomal protein SA pseudogene 52) at
193 kb away. Although the two loci in intergenic or
lincRNA regions do not exhibit biological functions, con-
sistent associations in Caucasian data suggest important
roles of these loci in LVID and LVH independent of ethni-
city [30]. Recently, several studies demonstrated thatvitamin D receptor (VDR) gene polymorphism is associ-
ated with LVM and predicts LVH progression in end-
stage renal disease patients [31,32]. Notably, the VDR gene
is located on chromosome 12. In view of these observa-
tions it could be worthy to consider if a linkage could
exist between these genetic loci on chromosome 12.
However, further investigation may be needed to verify
this possibility.
Among other eight SNPs, the rs765529 on chromosome
20 was intragenic, which is located in the potassium
voltage-gated channel, Shab-related subfamily, member 1
gene (KCNB1). Its protein product is dephosphorylated by
calcineurin, which is associated with LVH in human study
Table 5 Association analyses between left ventricular mass indexed by height2.7 and nine candidate SNPs from the
HyperGEN study in the Korean population
Log (LVM/height2.7) LVH
SNP LVM/height2.7, g/m2.7 Beta§ L95 U95 P value OR§ L95 U95 P value
rs409045 −0.024 −0.049 0.001 0.062 0.816 0.629 1.058 0.125
TT (n = 1239) 45.5 ± 12.0
CT + CC (n = 398) 45.2 ± 11.8
rs6450415 0.016 −0.007 0.039 0.178 1.320 1.041 1.673 0.022
TT (n = 1118) 45.3 ± 11.9
CT + CC (n = 519) 45.8 ± 11.9
rs6961069 0.002 −0.019 0.024 0.840 1.157 0.927 1.445 0.197
TT (n = 808) 45.4 ± 11.3
CT + CC (n = 829) 45.5 ± 12.5
rs10499859 0.002 −0.019 0.024 0.838 1.176 0.942 1.469 0.152
AA (n = 799) 45.3 ± 11.3
AG + GG (n = 838) 45.5 ± 12.5
rs4129218 −0.027 −0.048 −0.005 0.016 0.731 0.582 0.919 0.007
AA (n = 975) 46.1 ± 12.2
AG + GG (n = 662) 44.5 ± 11.5
rs1155635 −0.004 −0.027 0.019 0.717 0.873 0.690 1.106 0.261
AA (n = 543) 45.4 ± 11.6
GA + GG (n = 1081) 45.5 ± 12.1
rs2415872 −0.011 −0.033 0.010 0.293 0.937 0.750 1.171 0.569
GG (n = 735) 45.8 ± 12.0
GC + CC (n = 902) 45.1 ± 11.9
rs756529 0.014 −0.008 0.036 0.218 1.059 0.842 1.332 0.625
AA (n = 609) 44.8 ± 11.5
GA + GG (n = 1028) 45.8 ± 12.1
rs10483186 −0.005 −0.027 0.017 0.637 0.943 0.752 1.184 0.614
GG (n = 622) 45.7 ± 12.0
GT + TT (n = 1015) 45.3 ± 11.9
§Analysis adjusted for age, gender, body mass index, serum creatinine, systolic blood pressure, heart rate and antihypertensive medication.
Abbreviations: L95 and U95, confidence interval lower and upper 95%; LVH, left ventricular hypertrophy defined as LVM/ height2.7≥ 49 g/m2.7 in males and ≥ 45 g/m2.7
in females; LVM/height2.7, left ventricular mass indexed by height2.7; SNP, single nucleotide polymorphism.
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contribute to the inhibition of adipogenesis by retinoic
acid [34]. MIER3 (mesoderm induction early response 3)
gene has been suggested to be candidate breast cancer
susceptibility gene [35]. RP1-272 J12.1 is an uncharacter-
ized gene. Maria et al. presented that CD36 may impact
cardiovascular disease [36]. However, all had no significant
association with LVH in our study.
The present study has several limitations. First, as we
evaluated several candidate SNPs from the HyperGEN
study performed in the western populations, common
functional variants in the Korean population may not
have been tagged. Differences in linkage disequilibriumbetween Asian and Western subjects suggest that track-
ing of causal variant may not be possible. Although this
study showed a borderline association between some
candidate SNPs and LVH, other causal variants may
exist in Asian subjects. If it is considered that the effect
of single SNP is small, there might be a possibility that
the present study is underpowered. Second, the current
results cannot be generalized because they come from
adults aged >40 years in a rural area of Korea. Also,
echocardiographic data were measured by a single sonog-
rapher. Therefore, the intra-class correlation coefficient
was not available in the present study. Additionally, we
did not investigate the class and period of antihypertensive
Figure 1 Effect sizes of rs4129218 on two left ventricular mass index associations in Korean subjects. (A, The mean value of LVM indexed by
body surface area. B, The mean value of LVM indexed by height2.7). *Student’s t test. Error bars indicate 95% confidence intervals. White box, major
allele homozygote; gray box, minor allele carrier; LVM, left ventricular mass.
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angiotensin-receptor blockers may influence the de-
gree of LVH.
Conclusions
We analyzed nine candidate SNPs for LVH in the Korean
population. The genetic variation in LOC100507065
(rs4129218 on chromosome 12) had borderline association
with LVH, —consistent with findings in Caucasian popula-
tions. Although the function of the LOC100507065 gene
product is unknown, it may play a role in LVH develop-
ment, independent of ethnic background. Further investi-
gation is needed to determine the underlying mechanisms
and causal relationships thereof.
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